Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


08.07.2019

8 Acta Cytol
1 Am J Surg
1 Ann Surg Oncol
3 Anticancer Res
6 BMC Cancer
2 Breast Cancer
1 Breast Cancer (Auckl)
1 Breast Cancer Res
9 Breast Cancer Res Treat
8 Breast J
1 Cancer
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Res
1 Cell
3 Clin Breast Cancer
1 Curr Treat Options Oncol
1 Eur J Cancer
1 Gene
2 Int J Cancer
1 Int J Radiat Oncol Biol Phys
3 J Clin Oncol
1 J Nucl Med
1 JAMA
1 Lancet Oncol
1 Nat Rev Cancer
2 Nat Rev Clin Oncol
1 Nature
1 NPJ Breast Cancer
2 Oncogene
2 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Cytol

  1. FIELD AS, Raymond WA, Rickard M, Arnold L, et al
    The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology.
    Acta Cytol. 2019;63:257-273.
    PubMed     Text format     Abstract available

  2. GIBBONS CE, Quinn CM, Gibbons D
    Fine-Needle Aspiration Biopsy Management of the Axilla in Primary Breast Carcinoma.
    Acta Cytol. 2019;63:314-318.
    PubMed     Text format     Abstract available

  3. HODA RS, Arpin Iii RN, Gottumukkala RV, Hughes KS, et al
    Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions.
    Acta Cytol. 2019;63:319-327.
    PubMed     Text format     Abstract available

  4. WONG S, Rickard M, Earls P, Arnold L, et al
    The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology: A Single Institutional Retrospective Study of the Application of the System Categories and the Impact of Rapid Onsite Evaluation.
    Acta Cytol. 2019;63:280-291.
    PubMed     Text format     Abstract available

  5. MICHELOW P, Field AS
    Spindle Cell Lesions of the Breast on Fine-Needle Aspiration Biopsy: A Miscellany of Masses.
    Acta Cytol. 2019;63:328-339.
    PubMed     Text format     Abstract available

  6. BECA F, Schmitt FC
    Ancillary Tests in Breast Cytology: A Practical Guide.
    Acta Cytol. 2019;63:302-313.
    PubMed     Text format     Abstract available

  7. HODA RS, Brachtel EF
    International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology: A Review of Predictive Values and Risks of Malignancy.
    Acta Cytol. 2019;63:292-301.
    PubMed     Text format     Abstract available

  8. OSAMURA RY, Matsui N, Okubo M, Chen L, et al
    Histopathology and Cytopathology of Neuroendocrine Tumors and Carcinomas of the Breast: A Review.
    Acta Cytol. 2019;63:340-346.
    PubMed     Text format     Abstract available


    Am J Surg

  9. JAMES TA, Kasumova G, Alapati A, Mamtani A, et al
    Unplanned readmissions following breast cancer surgery.
    Am J Surg. 2019 Jun 20. pii: S0002-9610(19)30436.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  10. DE LA CRUZ LM, Thiruchelvam PTR, Shivani J, Trina J, et al
    Saving the Male Breast: A Systematic Literature Review of Breast-Conservation Surgery for Male Breast Cancer.
    Ann Surg Oncol. 2019 Jun 27. pii: 10.1245/s10434-019-07588.
    PubMed     Text format     Abstract available


    Anticancer Res

  11. CSONKA A, Kincses A, Nove M, Vadas Z, et al
    Selenoesters and Selenoanhydrides as Novel Agents Against Resistant Breast Cancer.
    Anticancer Res. 2019;39:3777-3783.
    PubMed     Text format     Abstract available

  12. SHIMADA K, Ishikawa T, Yamada A, Sugae S, et al
    Matrix-producing Carcinoma as an Aggressive Triple-negative Breast Cancer: Clinicopathological Features and Response to Neoadjuvant Chemotherapy.
    Anticancer Res. 2019;39:3863-3869.
    PubMed     Text format     Abstract available

  13. STRAVODIMOU A, Voutsadakis IA
    A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer.
    Anticancer Res. 2019;39:3295-3301.
    PubMed     Text format     Abstract available


    BMC Cancer

  14. HANNAFON BN, Cai A, Calloway CL, Xu YF, et al
    miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study.
    BMC Cancer. 2019;19:642.
    PubMed     Text format     Abstract available

  15. MCBRIDE ML, Groome PA, Decker K, Kendell C, et al
    Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study.
    BMC Cancer. 2019;19:659.
    PubMed     Text format     Abstract available

  16. SINGLETON A, Partridge SR, Raeside R, Regimbal M, et al
    A text message intervention to support women's physical and mental health after breast cancer treatments (EMPOWER-SMS): a randomised controlled trial protocol.
    BMC Cancer. 2019;19:660.
    PubMed     Text format     Abstract available

  17. LEE K, Kang I, Mack WJ, Mortimer J, et al
    Feasibility of high intensity interval training in patients with breast Cancer undergoing anthracycline chemotherapy: a randomized pilot trial.
    BMC Cancer. 2019;19:653.
    PubMed     Text format     Abstract available

  18. CHEN JH, Huang WC, Bamodu OA, Chang PM, et al
    Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
    BMC Cancer. 2019;19:634.
    PubMed     Text format     Abstract available

  19. SMELAND HY, Lu N, Karlsen TV, Salvesen G, et al
    Stromal integrin alpha11-deficiency reduces interstitial fluid pressure and perturbs collagen structure in triple-negative breast xenograft tumors.
    BMC Cancer. 2019;19:234.
    PubMed     Text format     Abstract available


    Breast Cancer

  20. YAO Z, Zheng X, Lu S, He Z, et al
    Knockdown of FAM64A suppresses proliferation and migration of breast cancer cells.
    Breast Cancer. 2019 Jul 1. pii: 10.1007/s12282-019-00991.
    PubMed     Text format     Abstract available

  21. FURLANETTO J, von Minckwitz G, Lederer B, Mobus V, et al
    Fatal events during clinical trials: an evaluation of deaths during breast cancer studies.
    Breast Cancer. 2019 Jun 28. pii: 10.1007/s12282-019-00990.
    PubMed     Text format     Abstract available


    Breast Cancer (Auckl)

  22. BAKER E, Whiteoak N, Hall L, France J, et al
    Mammaglobin-A, VEGFR3, and Ki67 in Human Breast Cancer Pathology and Five Year Survival.
    Breast Cancer (Auckl). 2019;13:1178223419858957.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  23. MCLAUGHLIN RP, He J, van der Noord VE, Redel J, et al
    A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    Breast Cancer Res. 2019;21:77.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  24. GIANNAKEAS V, Narod SA
    A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy.
    Breast Cancer Res Treat. 2019 Jul 1. pii: 10.1007/s10549-019-05334.
    PubMed     Text format     Abstract available

  25. YEO W, Ueno T, Lin CH, Liu Q, et al
    Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
    Breast Cancer Res Treat. 2019 Jul 4. pii: 10.1007/s10549-019-05318.
    PubMed     Text format     Abstract available

  26. HARBORG S, Cronin-Fenton DP, Borgquist S
    RE.: Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer.
    Breast Cancer Res Treat. 2019 Jul 4. pii: 10.1007/s10549-019-05337.
    PubMed     Text format    

  27. ZEINDLER J, Angehrn F, Droeser R, Daster S, et al
    Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer.
    Breast Cancer Res Treat. 2019 Jul 2. pii: 10.1007/s10549-019-05336.
    PubMed     Text format     Abstract available

  28. SASADA S, Shiroma N, Goda N, Kajitani K, et al
    The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer.
    Breast Cancer Res Treat. 2019 Jul 2. pii: 10.1007/s10549-019-05339.
    PubMed     Text format     Abstract available

  29. COUGHLIN SS
    Social determinants of breast cancer risk, stage, and survival.
    Breast Cancer Res Treat. 2019 Jul 3. pii: 10.1007/s10549-019-05340.
    PubMed     Text format     Abstract available

  30. PUVANESARAJAH S, Gapstur SM, Patel AV, Sherman ME, et al
    Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II.
    Breast Cancer Res Treat. 2019 Jul 1. pii: 10.1007/s10549-019-05322.
    PubMed     Text format     Abstract available

  31. LI E, Guida JL, Tian Y, Sung H, et al
    Associations between mammographic density and tumor characteristics in Chinese women with breast cancer.
    Breast Cancer Res Treat. 2019 Jun 28. pii: 10.1007/s10549-019-05325.
    PubMed     Text format     Abstract available

  32. KOROBEYNIKOV V, Borakove M, Feng Y, Wuest WM, et al
    Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
    Breast Cancer Res Treat. 2019 Jun 28. pii: 10.1007/s10549-019-05329.
    PubMed     Text format     Abstract available


    Breast J

  33. MANYAM BV, Shah C, Woody NM, Reddy CA, et al
    Long-term complications and reconstruction failures in previously radiated breast cancer patients receiving salvage mastectomy with autologous reconstruction or tissue expander/implant-based reconstruction.
    Breast J. 2019 Jul 1. doi: 10.1111/tbj.13428.
    PubMed     Text format     Abstract available

  34. BLAES AH, Jewett PI, McKay K, Riley D, et al
    Factors associated with genetic testing in a cohort of breast cancer survivors.
    Breast J. 2019 Jul 3. doi: 10.1111/tbj.13440.
    PubMed     Text format     Abstract available

  35. CHOTAI N, Tang S, Lim H, Lu S, et al
    Breast cancer in a female to male transgender patient 20 years post-mastectomy: Issues to consider.
    Breast J. 2019 Jul 4. doi: 10.1111/tbj.13417.
    PubMed     Text format     Abstract available

  36. DONOVAN E, Dhesy-Thind S, Mukherjee S, Kucharczyk M, et al
    Attitudes and beliefs toward the use of stereotactic body radiotherapy in oligometastatic breast cancer: A commentary on a survey of Canadian Medical Oncologists.
    Breast J. 2019 Jul 1. doi: 10.1111/tbj.13435.
    PubMed     Text format     Abstract available

  37. CROWN A, Grumley J
    Biopsy-proven lymph nodes predict axillary nodal response following neoadjuvant chemotherapy in node-positive breast cancer.
    Breast J. 2019 Jun 29. doi: 10.1111/tbj.13412.
    PubMed     Text format    

  38. PHILLIPS GSA, Gore S, Ramsden A, Furniss D, et al
    Lymphaticovenular anastomosis improves quality of life and limb volume in patients with secondary lymphedema after breast cancer treatment.
    Breast J. 2019 Jun 27. doi: 10.1111/tbj.13348.
    PubMed     Text format     Abstract available

  39. HAQUE W, Verma V, Hsiao KY, Hatch S, et al
    Omission of radiation therapy following breast conservation in older (>/=70 years) women with T1-2N0 triple-negative breast cancer.
    Breast J. 2019 Jul 4. doi: 10.1111/tbj.13443.
    PubMed     Text format     Abstract available

  40. DREYFUSS AD, Barsky AR, Taunk NK, Clark AS, et al
    The efficacy and safety of hypofractionated radiotherapy with concurrent anti-HER-2 therapy following breast-conserving therapy for breast cancer.
    Breast J. 2019 Jun 28. doi: 10.1111/tbj.13421.
    PubMed     Text format     Abstract available


    Cancer

  41. PRINTZ C
    Study: Patients with HER2-positive, stage IV breast cancer experienced better survival with surgery.
    Cancer. 2019;125:2337.
    PubMed     Text format    


    Cancer Chemother Pharmacol

  42. KOTAKE M, Imai H, Kaira K, Fujisawa T, et al
    Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study.
    Cancer Chemother Pharmacol. 2019 Jun 27. pii: 10.1007/s00280-019-03897.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  43. PETRIDIS C, Arora I, Shah V, Moss CL, et al
    Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in Sporadic Lobular Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2019;28:1162-1168.
    PubMed     Text format     Abstract available


    Cancer Res

  44. COLOMBO MP, Lecis D
    When Failure Is Worse Than Giving Up: The Case of CTL.
    Cancer Res. 2019;79:1753-1755.
    PubMed     Text format     Abstract available

  45. MCANDREWS KM, Kalluri R
    Nischarin Regulates Secretion of Exosomes and Cancer Progression.
    Cancer Res. 2019;79:2099-2101.
    PubMed     Text format     Abstract available


    Cell

  46. WANG H, Xiang D, Liu B, He A, et al
    Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer.
    Cell. 2019;178:135-151.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  47. FARES J, Kanojia D, Rashidi A, Ahmed AU, et al
    Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations.
    Clin Breast Cancer. 2019 Jun 5. pii: S1526-8209(19)30262.
    PubMed     Text format     Abstract available

  48. XU L, Zhang Z, Xiang Q, Liu Q, et al
    Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials.
    Clin Breast Cancer. 2019 Apr 19. pii: S1526-8209(18)30531.
    PubMed     Text format     Abstract available

  49. ZHOU Y, Simmons J, Jordan CD, Sonbol MB, et al
    Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
    Clin Breast Cancer. 2019 May 18. pii: S1526-8209(19)30066.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  50. GERRATANA L, Davis AA, Shah AN, Lin C, et al
    Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.
    Curr Treat Options Oncol. 2019;20:68.
    PubMed     Text format     Abstract available


    Eur J Cancer

  51. MARTIN M, Loibl S, Hyslop T, De la Haba-Rodriguez J, et al
    Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
    Eur J Cancer. 2019;117:91-98.
    PubMed     Text format     Abstract available


    Gene

  52. NAZIR SU, Kumar R, Singh A, Khan A, et al
    Breast cancer invasion and progression by MMP-9 through Ets-1 transcription factor.
    Gene. 2019 Jun 29:143952. doi: 10.1016/j.gene.2019.143952.
    PubMed     Text format     Abstract available


    Int J Cancer

  53. SHU X, Bao J, Wu L, Long J, et al
    Evaluation of Associations between Genetically Predicted Circulating Protein Biomarkers and Breast Cancer Risk.
    Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32542.
    PubMed     Text format     Abstract available

  54. BRENTNALL AR, van Veen EM, Harkness EF, Rafiq S, et al
    A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density.
    Int J Cancer. 2019 Jun 28. doi: 10.1002/ijc.32541.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  55. GROSS JP, Lynch CM, Flores AM, Jordan SW, et al
    Determining the "Organ-at-Risk" for Lymphedema Following Regional Nodal Irradiation in Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jun 28. pii: S0360-3016(19)33397.
    PubMed     Text format     Abstract available


    J Clin Oncol

  56. HINDIE E, Groheux D
    Interim [(18)F]Fluorodeoxyglucose-Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Jun 28:JCO1900776. doi: 10.1200/JCO.19.00776.
    PubMed     Text format    

  57. OEFFINGER KC, Ford JS, Moskowitz CS, Chou JF, et al
    Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 1:JCO1900547. doi: 10.1200/JCO.19.00547.
    PubMed     Text format     Abstract available

  58. MOSKOWITZ CS, Chou JF, Neglia JP, Partridge AH, et al
    Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 1:JCO1802219. doi: 10.1200/JCO.18.02219.
    PubMed     Text format     Abstract available


    J Nucl Med

  59. LEITHNER D, Helbich TH, Bernard-Davila B, Marino MA, et al
    Multiparametric (18)F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and without breast cancer?
    J Nucl Med. 2019 Jun 28. pii: jnumed.119.230003. doi: 10.2967/jnumed.119.230003.
    PubMed     Text format     Abstract available


    JAMA


  60. First PI3K Inhibitor for Breast Cancer.
    JAMA. 2019;322:19.
    PubMed     Text format    


    Lancet Oncol

  61. BANERJI U, van Herpen CML, Saura C, Thistlethwaite F, et al
    Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
    Lancet Oncol. 2019 Jun 27. pii: S1470-2045(19)30328.
    PubMed     Text format     Abstract available


    Nat Rev Cancer

  62. SRIVASTAVA S, Koay EJ, Borowsky AD, De Marzo AM, et al
    Cancer overdiagnosis: a biological challenge and clinical dilemma.
    Nat Rev Cancer. 2019;19:349-358.
    PubMed     Text format     Abstract available


    Nat Rev Clin Oncol

  63. SIDAWAY P
    Fulvestrant enables better outcomes.
    Nat Rev Clin Oncol. 2019;16:337.
    PubMed     Text format    

  64. BRADLEY CA
    Brain metastases respond to neratinib plus capecitabine.
    Nat Rev Clin Oncol. 2019;16:336.
    PubMed     Text format    


    Nature

  65. PRITCHARD CC
    New name for breast-cancer syndrome could help to save lives.
    Nature. 2019;571:27-29.
    PubMed     Text format    


    NPJ Breast Cancer

  66. LEVINE KM, Priedigkeit N, Basudan A, Tasdemir N, et al
    FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype.
    NPJ Breast Cancer. 2019;5:19.
    PubMed     Text format     Abstract available


    Oncogene

  67. CRAWFORD NT, McIntyre AJ, McCormick A, D'Costa ZC, et al
    TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.
    Oncogene. 2019 Jun 28. pii: 10.1038/s41388-019-0853.
    PubMed     Text format     Abstract available

  68. ZHU Y, Xie M, Meng Z, Leung LK, et al
    Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells.
    Oncogene. 2019 Jun 27. pii: 10.1038/s41388-019-0846.
    PubMed     Text format     Abstract available


    Radiology

  69. SITEK A, Wolfe JM
    Assessing Cancer Risk from Mammograms: Deep Learning Is Superior to Conventional Risk Models.
    Radiology. 2019;292:67-68.
    PubMed     Text format    

  70. FOWLER AM
    Survival Outcomes for Women with Ductal Carcinoma in Situ in the Era of Supplemental Screening.
    Radiology. 2019;292:49-50.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: